Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy

Donald J Newport, Amy L. Hostetter, Sarah H. Juul, Sunny M. Porterfield, Bettina T. Knight, Zachary N. Stowe

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To investigate the association, if any, of prenatal mental illness and psychotropic exposure with the risk of hypertensive disorders of pregnancy (HDP). Methods: A case-cohort analysis was conducted of 686 pregnant women participating in prospective, longitudinal observational studies in a tertiary referral center between January 1998 and May 2012. Risk estimates were produced using multivariate logistic regression modeling. Medication- and diagnosisspecific data were utilized to conduct post hoc confirmatory analyses of the risk estimates. Results: After adjustment for confounders, HDP were significantly associated with psychostimulant (odds ratio [OR] = 6.11; 95% CI, 1.79-20.9) and serotoninnorepinephrine reuptake inhibitor (SNRI) (OR = 2.57; 95%, 1.34-4.93) exposure following the 20th week of gestation and lifetime histories of cocaine dependence (OR = 2.99; 95% CI, 1.12-7.98) and panic disorder (OR = 1.78; 95% CI, 1.06-2.98) using DSMIV diagnostic criteria. HDP risk was not associated with prenatal selective serotonin reuptake inhibitor exposure or other psychiatric disorders. Post hoc analyses demonstrated an increased risk for HDP with higher maternal daily doses of amphetamine psychostimulants and the SNRI venlafaxine. Conclusions: These data indicate that psychostimulant and SNRI exposure following the 20th week of gestation conveys considerable risk for the emergence of HDP. Overall, the findings suggest that heightened vascular reactivity to noradrenergic, rather than serotonergic, stimulation may be pivotal to HDP risk among women with psychiatric illness.

Original languageEnglish (US)
Pages (from-to)1538-1545
Number of pages8
JournalJournal of Clinical Psychiatry
Volume77
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Antidepressive Agents
Pregnancy
Odds Ratio
Psychiatry
Cocaine-Related Disorders
Panic Disorder
Serotonin Uptake Inhibitors
Amphetamine
Tertiary Care Centers
Observational Studies
Blood Vessels
Longitudinal Studies
Pregnant Women
Cohort Studies
Logistic Models
Mothers

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy. / Newport, Donald J; Hostetter, Amy L.; Juul, Sarah H.; Porterfield, Sunny M.; Knight, Bettina T.; Stowe, Zachary N.

In: Journal of Clinical Psychiatry, Vol. 77, No. 11, 01.11.2016, p. 1538-1545.

Research output: Contribution to journalArticle

Newport, Donald J ; Hostetter, Amy L. ; Juul, Sarah H. ; Porterfield, Sunny M. ; Knight, Bettina T. ; Stowe, Zachary N. / Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy. In: Journal of Clinical Psychiatry. 2016 ; Vol. 77, No. 11. pp. 1538-1545.
@article{406c1f40a09d4017a108aa2f04c5d89b,
title = "Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy",
abstract = "Objective: To investigate the association, if any, of prenatal mental illness and psychotropic exposure with the risk of hypertensive disorders of pregnancy (HDP). Methods: A case-cohort analysis was conducted of 686 pregnant women participating in prospective, longitudinal observational studies in a tertiary referral center between January 1998 and May 2012. Risk estimates were produced using multivariate logistic regression modeling. Medication- and diagnosisspecific data were utilized to conduct post hoc confirmatory analyses of the risk estimates. Results: After adjustment for confounders, HDP were significantly associated with psychostimulant (odds ratio [OR] = 6.11; 95{\%} CI, 1.79-20.9) and serotoninnorepinephrine reuptake inhibitor (SNRI) (OR = 2.57; 95{\%}, 1.34-4.93) exposure following the 20th week of gestation and lifetime histories of cocaine dependence (OR = 2.99; 95{\%} CI, 1.12-7.98) and panic disorder (OR = 1.78; 95{\%} CI, 1.06-2.98) using DSMIV diagnostic criteria. HDP risk was not associated with prenatal selective serotonin reuptake inhibitor exposure or other psychiatric disorders. Post hoc analyses demonstrated an increased risk for HDP with higher maternal daily doses of amphetamine psychostimulants and the SNRI venlafaxine. Conclusions: These data indicate that psychostimulant and SNRI exposure following the 20th week of gestation conveys considerable risk for the emergence of HDP. Overall, the findings suggest that heightened vascular reactivity to noradrenergic, rather than serotonergic, stimulation may be pivotal to HDP risk among women with psychiatric illness.",
author = "Newport, {Donald J} and Hostetter, {Amy L.} and Juul, {Sarah H.} and Porterfield, {Sunny M.} and Knight, {Bettina T.} and Stowe, {Zachary N.}",
year = "2016",
month = "11",
day = "1",
doi = "10.4088/JCP.15m10506",
language = "English (US)",
volume = "77",
pages = "1538--1545",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "11",

}

TY - JOUR

T1 - Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy

AU - Newport, Donald J

AU - Hostetter, Amy L.

AU - Juul, Sarah H.

AU - Porterfield, Sunny M.

AU - Knight, Bettina T.

AU - Stowe, Zachary N.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective: To investigate the association, if any, of prenatal mental illness and psychotropic exposure with the risk of hypertensive disorders of pregnancy (HDP). Methods: A case-cohort analysis was conducted of 686 pregnant women participating in prospective, longitudinal observational studies in a tertiary referral center between January 1998 and May 2012. Risk estimates were produced using multivariate logistic regression modeling. Medication- and diagnosisspecific data were utilized to conduct post hoc confirmatory analyses of the risk estimates. Results: After adjustment for confounders, HDP were significantly associated with psychostimulant (odds ratio [OR] = 6.11; 95% CI, 1.79-20.9) and serotoninnorepinephrine reuptake inhibitor (SNRI) (OR = 2.57; 95%, 1.34-4.93) exposure following the 20th week of gestation and lifetime histories of cocaine dependence (OR = 2.99; 95% CI, 1.12-7.98) and panic disorder (OR = 1.78; 95% CI, 1.06-2.98) using DSMIV diagnostic criteria. HDP risk was not associated with prenatal selective serotonin reuptake inhibitor exposure or other psychiatric disorders. Post hoc analyses demonstrated an increased risk for HDP with higher maternal daily doses of amphetamine psychostimulants and the SNRI venlafaxine. Conclusions: These data indicate that psychostimulant and SNRI exposure following the 20th week of gestation conveys considerable risk for the emergence of HDP. Overall, the findings suggest that heightened vascular reactivity to noradrenergic, rather than serotonergic, stimulation may be pivotal to HDP risk among women with psychiatric illness.

AB - Objective: To investigate the association, if any, of prenatal mental illness and psychotropic exposure with the risk of hypertensive disorders of pregnancy (HDP). Methods: A case-cohort analysis was conducted of 686 pregnant women participating in prospective, longitudinal observational studies in a tertiary referral center between January 1998 and May 2012. Risk estimates were produced using multivariate logistic regression modeling. Medication- and diagnosisspecific data were utilized to conduct post hoc confirmatory analyses of the risk estimates. Results: After adjustment for confounders, HDP were significantly associated with psychostimulant (odds ratio [OR] = 6.11; 95% CI, 1.79-20.9) and serotoninnorepinephrine reuptake inhibitor (SNRI) (OR = 2.57; 95%, 1.34-4.93) exposure following the 20th week of gestation and lifetime histories of cocaine dependence (OR = 2.99; 95% CI, 1.12-7.98) and panic disorder (OR = 1.78; 95% CI, 1.06-2.98) using DSMIV diagnostic criteria. HDP risk was not associated with prenatal selective serotonin reuptake inhibitor exposure or other psychiatric disorders. Post hoc analyses demonstrated an increased risk for HDP with higher maternal daily doses of amphetamine psychostimulants and the SNRI venlafaxine. Conclusions: These data indicate that psychostimulant and SNRI exposure following the 20th week of gestation conveys considerable risk for the emergence of HDP. Overall, the findings suggest that heightened vascular reactivity to noradrenergic, rather than serotonergic, stimulation may be pivotal to HDP risk among women with psychiatric illness.

UR - http://www.scopus.com/inward/record.url?scp=84998717670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998717670&partnerID=8YFLogxK

U2 - 10.4088/JCP.15m10506

DO - 10.4088/JCP.15m10506

M3 - Article

C2 - 28076672

AN - SCOPUS:84998717670

VL - 77

SP - 1538

EP - 1545

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 11

ER -